Literature DB >> 19013349

Tigecycline In-vitro Surveillance in Taiwan (TIST).

Po-Ren Hsueh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19013349     DOI： 10.1016/S0924-8579(08)70022-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  6 in total

1.  Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.

Authors:  Yen-Hsu Chen; Po-Liang Lu; Cheng-Hua Huang; Chun-Hsing Liao; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Jien-Wei Liu; Wu Sun; Lih-Shinn Wang; Wen-Chien Ko; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

2.  Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010.

Authors:  Y-H Chen; C-Y Liu; W-C Ko; C-H Liao; P-L Lu; C-H Huang; C-T Lu; Y-C Chuang; S-M Tsao; Y-S Chen; Y-C Liu; W-Y Chen; T-N Jang; H-C Lin; C-M Chen; Z-Y Shi; S-C Pan; J-L Yang; H-C Kung; C-E Liu; Y-J Cheng; J-W Liu; W Sun; L-S Wang; K-W Yu; P-C Chiang; M-H Lee; C-M Lee; G-J Hsu; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-18       Impact factor: 3.267

3.  Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.

Authors:  Jien-Wei Liu; Wen-Chien Ko; Cheng-Hua Huang; Chun-Hsing Liao; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Yen-Hsu Chen; Po-Liang Lu; Wu Sun; Lih-Shinn Wang; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity.

Authors:  Hung-Jen Tang; Chih-Cheng Lai; Chi-Chung Chen; Chun-Cheng Zhang; Tzu-Chieh Weng; Wen-Liang Yu; Hung-Jui Chen; Yu-Hsin Chiu; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Front Microbiol       Date:  2017-05-18       Impact factor: 5.640

5.  Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Sci Rep       Date:  2017-01-31       Impact factor: 4.379

6.  The clinical significance of silent mutations with respect to ciprofloxacin resistance in MRSA.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Ying-Chen Lu; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Infect Drug Resist       Date:  2018-05-03       Impact factor: 4.003
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.